Royalty Pharma is less exposed to MFN drug pricing risks, offering downside protection in a volatile policy environment. See ...

Technology can transform veterinary sciences just as it has revolutionised other sectors, says Prez at convocation of IVRI, ...

Revolution Medicines and Summit Therapeutics entered into a clinical collaboration in multiple solid-tumor settings to evaluate their respective treatments in combination with each other. Redwood City ...

While delivering a thought-provoking keynote address at the Doctor’s Day Conclave organized by the Times Now, Union Minister ...

Dr. Ambish Mithal unpacks the world of new-age weight management drugs, their side effects, their benefits and what lies ...

Hair transplant begins in the operating room and continues through every subsequent stage of recovery. Healing can now be ...

Taking an unconventional path to market for its targeted therapies for RAS-addicted cancers, Revolution Medicines Inc. secured access to $2 billion in capital to build its own global commercial ...

The funding will support the development of Revolution's RAS(ON) inhibitor daraxonrasib in exchange for tiered royalties on its sales.

Royalty Pharma will pay up to $2 billion to Revolution Medicines to support the development and sales of an experimental drug ...

Royalty Pharma Plc. (RPRX) on Tuesday announced a $2 billion funding arrangement with Revolution Medicines (RVMD), aimed at ...

Revolution Medicines projected its cash and equivalents of $2.1 billion would last into the second half of 2027. With new ...